DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
-
-
Carboplatin (HB3824)
Description:Cisplatin analog. Blocks DNA replication and transcription.
Purity:>98%
-
(S)-4-Carboxyphenylglycine (HB0049)
Description:Competitive, selective group 1 mGlu antagonist
Purity:>99%
-
CAT335 (HB8146)
Description:K2P2.1 (TREK-1) modulator. Selectively and irreversibly activates TREK-1CG* but not wild-type K2P2.1 (TREK-1)
Purity:>98%
-
CCG 1423 (HB3389)
Description:Rho/SRF pathway inhibitor. Induces intermediate mesoderm differentiation from ESCs.
Purity:>99%
-
Celastrol (HB4605)
Description:Anti-oxidant, anti-inflammatory compound with many actions. Topoisomerase II inhibitor.
Purity:>98%
-
Cesium Gluconate (Cs-Gluc) (HB4822)
Description:Potassium channel blocker. Component in cesium gluconate-based internal solutions used for patch clamp electrophysiology.
-
